During NAFLD, there is a dysfunction in β-oxidation that induces a decreased hepatic peroxisome proliferator-activated receptor alpha (PPARα) activity, increasing liver lipids, modulating lipid homeostasis and inflammation, and favoring the progression of this pathology [32]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.